Halozyme Therapeutics
HALO
£39.56
Share price
0.08%
Change (1 day)
0.01%
Change (1 year)
Categories
Halozyme Therapeutics (HALO) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : £1.27 Billion
According to Halozyme Therapeutics's latest financial reports the company's total liabilities are £1.27 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Halozyme Therapeutics - Total liabilities on balance sheet (from 2002 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | £1.35 B | 4.61% |
| 2023-12-31 | £1.29 B | -6.3% |
| 2022-12-31 | £1.38 B | 105.54% |
| 2021-12-31 | £0.67 B | 113.67% |
| 2020-12-31 | £0.31 B | -12.98% |
| 2019-12-31 | £0.36 B | 139.83% |
| 2018-12-31 | £0.15 B | -34.61% |
| 2017-12-31 | £0.23 B | -3.24% |
| 2016-12-31 | £0.23 B | 154.41% |
| 2015-12-31 | £93.65 M | 17% |
| 2014-12-31 | £80.04 M | 8.42% |
| 2013-12-31 | £73.82 M | 38.96% |
| 2012-12-31 | £53.13 M | 50.53% |
| 2011-12-31 | £35.29 M | -23.25% |
| 2010-12-31 | £45.98 M | 5.94% |
| 2009-12-31 | £43.41 M | 3.99% |
| 2008-12-31 | £41.74 M | 81.5% |
| 2007-12-31 | £23 M | 95.79% |
| 2006-12-31 | £11.74 M | 779.48% |
| 2005-12-31 | £1.33 M | 62.36% |
| 2004-12-31 | £0.82 M | 438.2% |
| 2003-12-31 | £0.15 M | -59.83% |
| 2002-12-31 | £0.38 M | 16674.97% |
| 2001-12-31 | £0 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 MannKind Corp MNKD | £0.34 B | -72.66% | 🇺🇸 USA |
 Eli Lilly LLY | £54.74 B | 4,190.01% | 🇺🇸 USA |
 Baxter BAX | £10.60 B | 731.26% | 🇺🇸 USA |
 Pfizer PFE | £87.38 B | 6,747.91% | 🇺🇸 USA |
 Sanofi SNY | £46.30 B | 3,528.94% | 🇫🇷 France |
 Johnson & Johnson JNJ | £86.02 B | 6,641.22% | 🇺🇸 USA |